Login to Your Account

Adcom Tips Its Hat to New Novartis CF Formulation

By Mari Serebrov
Washington Editor

Thursday, September 6, 2012
While having, in effect, only one controlled trial to support approval of Novartis AG's TOBI Podhaler (TIP) raised flags for FDA reviewers, it didn't faze the agency's Anti-Infective Drugs Advisory Committee.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription